ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Ziprasidone: Drug information

Ziprasidone: Drug information
(For additional information see "Ziprasidone: Patient drug information" and see "Ziprasidone: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis:

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis.

Brand Names: US
  • Geodon
Brand Names: Canada
  • Auro-Ziprasidone;
  • Zeldox
Pharmacologic Category
  • Antimanic Agent;
  • Second Generation (Atypical) Antipsychotic
Dosing: Adult

Dosage guidance:

Safety: Dose-dependent QTc interval prolongation; consider monitoring ECG during therapy (baseline and after dose increases), particularly in patients with risk factors for QTc prolongation (eg, preexisting QT prolongation, other cardiovascular disease, uncorrected electrolyte abnormalities, concurrent use with other drugs that prolong QT interval) (Ref). Some experts recommend checking baseline ECG in patients with schizophrenia, regardless of risk factors (Ref).

Clinical considerations: Oral dose needs to be taken with a meal (≥500 calories) to be adequately absorbed (Ref).

Agitation/Aggression associated with psychiatric disorders, substance intoxication, or other organic causes

Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia [labeled use], bipolar disorder [off-label use]), substance intoxication (off-label use), or other organic causes (off-label use) (alternative agent):

Note: Antipsychotics are appropriate when psychosis is suspected to be the primary cause of agitation/aggression. Other agents are used preferentially in agitation associated with certain intoxications (eg, anticholinergic substances, stimulants) or alcohol withdrawal. Depending on presentation, may combine with a benzodiazepine (Ref). For cooperative patients able to take oral medication, use an alternative antipsychotic that does not need to be taken with a meal.

IM: 10 mg every 2 hours or 20 mg every 4 hours (maximum: 40 mg/day). Oral therapy should replace IM administration as soon as possible.

Bipolar disorder

Bipolar disorder:

Acute manic episodes with or without mixed features (labeled use) and acute hypomania, monotherapy (off-label use) (alternative agent):

Oral: Initial: 40 mg twice daily with meal; on day 2 of treatment, may increase to 60 or 80 mg twice daily; subsequently adjust dose based on response and tolerability. Usual dosage: 40 to 80 mg twice daily (Ref).

Note: For some patients, doses up to 240 mg/day may be necessary and tolerated (Ref). Combining with lithium or valproate for acute episode does not provide additional benefit (Ref).

Maintenance treatment, monotherapy (off-label use) or adjunctive with antimanic therapy (labeled use):

Monotherapy: Oral: Continue dose that was used to achieve control of the acute episode (Ref).

Adjunctive with antimanic therapy:

Oral: 40 or 80 mg twice daily with meal (Ref).

Note: Despite lack of added benefit for ziprasidone plus lithium or valproate in acute episodes, maintenance treatment with combination treatment may delay time to relapse (Ref).

Delirium in the ICU, hyperactive, treatment

Delirium in the ICU, hyperactive, treatment (alternative agent) (off-label use):

Note: Nonpharmacologic interventions and treatment of underlying conditions are initial steps to prevent and manage delirium. Antipsychotics may be used as short-term adjunctive treatment if distressing symptoms (eg, agitation, anxiety) are present (Ref). Reassess daily for continued need; consider discontinuation and/or taper as symptoms resolve, especially at transitions of care, to prevent unnecessary continuation of therapy (Ref). Although data are limited, some experts use the following:

IM: 10 mg, then may repeat every 2 hours if needed or 20 mg, then may repeat once in 4 hours if needed; maximum total daily dose: 40 mg (Ref).

Oral: 20 to 40 mg every 12 hours with meal, if possible; maximum total daily dose: 80 mg (Ref).

Delusional infestation

Delusional infestation (delusional parasitosis) (off-label use): Oral: Initial: 20 mg twice daily with meal; gradually increase every few weeks to lowest effective daily dose in range of 20 to 80 mg twice daily (Ref). After achieving adequate response, maintain for ≥1 to 3 months before attempting to taper and discontinue (Ref).

Major depressive disorder, treatment resistant

Major depressive disorder, treatment resistant (unipolar, nonpsychotic) (adjunctive therapy with antidepressant) (alternative agent) (off-label use):

Note: Also can be used for initial treatment of major depression with psychotic features (ie, not necessarily treatment resistant) in combination with an antidepressant (Ref).

Oral: Initial: 20 mg twice daily with meal; may increase daily dose based on response and tolerability in increments of 40 mg every week up to 160 mg/day in 2 divided doses (Ref).

Schizophrenia

Schizophrenia:

Oral: Initial: 20 to 40 mg twice daily with meal; may increase dose based on response and tolerability every 2 days or more. Usual dosage: 20 to 80 mg twice daily; maximum dose: 80 mg twice daily (Ref).

Note: For IM administration in acute agitation associated with schizophrenia, refer to "Agitation/Aggression (Severe, Acute) Associated with Psychiatric Disorders, (eg, Schizophrenia [Labeled Use], Bipolar Disorder [Off-Label Use]), Substance Intoxications (Off-Label Use), or Other Organic Causes (Off-Label Use)."

Discontinuation of therapy : In the treatment of chronic psychiatric disease, switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (eg, over several weeks to months) is advised to detect a reemergence of symptoms and to avoid withdrawal reactions (ie, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (Ref).

Switching antipsychotics: An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (Ref). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Oral: No dosage adjustment necessary.

IM: No dosage adjustment necessary. Cyclodextrin, an excipient in the IM formulation, is cleared by renal filtration; use with caution.

Ziprasidone is not removed by hemodialysis.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, drug undergoes extensive hepatic metabolism and systemic exposure may be increased. Use with caution.

Dosing: Older Adult

Note: Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. May be appropriate for FDA approved indications, including schizophrenia and bipolar disorder (Ref).

Refer to adult dosing. Dosages in the lower range of recommended adult dosing are generally sufficient with late-onset schizophrenia or psychosis. Titrate dosage slowly and monitor carefully (Ref).

Dosing: Pediatric

(For additional information see "Ziprasidone: Pediatric drug information")

Acute agitation

Acute agitation: Limited data available:

Weight-directed dosing: Children ≥5 years and Adolescents: IM: 0.2 mg/kg/dose; maximum dose: 20 mg/dose; a retrospective review of 40 patients (age range: 5 to 18 years) presenting to the emergency department with acute agitation showed a significant (P=0.03) response with a mean initial single dose of 0.19 ± 0.1 mg/kg amongst responders compared to a mean initial dose of 0.13 ± 0.06 mg/kg in nonresponders (Ref).

Fixed dosing (Ref):

Children 5 to 11 years: IM: 10 mg.

Children ≥12 years and Adolescents: IM: 10 to 20 mg; one study (n=59; age range: 5 to 19 years) reported that 69% of 20 mg doses surpassed the desired calming therapeutic effect and caused varying degrees of sedation (4% of patients were unable to be aroused) (Ref).

Autism spectrum disorders; irritability

Autism spectrum disorders; irritability: Limited data available:

Children ≥6 years and Adolescents: Oral: Reported final daily dose range: 20 to 240 mg/day in divided doses twice daily; see the following for initial doses and titration reported (Ref).

A prospective, open-label study of 12 patients (12 to 18 years) used the following individually titrated doses (Ref):

Patient weight ≤35 kg: Initial: 20 mg every other day at bedtime for 2 doses; then increase dose in weekly increments based on clinical response and tolerability: Week 1: 10 mg twice daily (20 mg/day); Week 2: 20 mg twice daily (40 mg/day); Week 3: 40 mg twice daily (80 mg/day); Week 4: 80 mg twice daily (160 mg/day).

Patient weight >35 kg: Initial: 20 mg/day at bedtime for 3 doses; then increase dose in weekly increments based on clinical response and tolerability: Week 1: 20 mg twice daily (40 mg/day); Week 2: 40 mg twice daily (80 mg/day); Week 4: 80 mg twice daily (160 mg/day).

A retrospective trial evaluated 42 pediatric patients (mean age: 11.8 ± 3.9 years; range: 5.9 to 18.7 years) and reported treatment response in 40% of subjects based on improvement in Clinical Global Impressions-Improvement Scale (CGI-I) scores at a mean final dose of 98.7 ± 52 mg/day (1.7 ± 1.1 mg/kg/day); reported range: 20 to 240 mg/day (Ref). A case series of 12 patients (8 to 20 years) initiated therapy at 20 mg/day administered at bedtime and then increased by 10 to 20 mg/week divided twice daily based on clinical response and tolerability; final ziprasidone dosage ranged between 20 to 120 mg/day (mean: ~60 mg/day) divided twice daily (Ref).

Bipolar I disorder

Bipolar I disorder: Note: In June 2009, an FDA advisory panel advised that ziprasidone was effective in patients 10 to 17 years of age for the treatment of mixed and manic episodes of bipolar disorder, but did not conclude that it was safe due to large number of subjects lost to follow-up and ambiguity within QTc prolongation data. Since then, prescribing of ziprasidone has decreased similarly for pediatric and adult patients (Ref).

Fixed dosing: Limited data available (Ref): Children and Adolescents 10 to 17 years: Oral: Initial dose: 20 mg/day; titrate dose upwards as tolerated, using twice-daily dosing over a 2-week period to the weight-based target range: 60 to 80 mg/day (weight <45 kg) divided into twice-daily doses or 120 to 160 mg/day (weight ≥45 kg) divided into twice-daily doses (Ref).

Weight-directed dosing: Limited data available: Children ≥6 years and Adolescents: An open-label, 8-week study of 21 patients (6 to 17 years [mean: 10.3 years]) with bipolar disorder and comorbid conditions (eg, attention-deficit/hyperactivity disorder, depression, conduct disorder) used the following weight-based dosing regimen (Ref):

Initial dose: 1 mg/kg/day divided twice daily; increase to 1.5 mg/kg/day divided twice daily by Week 2 and increase to 2 mg/kg/day divided twice daily by Week 3 if tolerated; maximum dose: 160 mg/day; Note: Only 14 of the 21 patients completed the study; five dropped out due to lack of efficacy; two dropped out due to adverse reactions; patients experienced a high incidence of sedation (46%) and headaches (38%).

Tourette syndrome, tic disorder

Tourette syndrome, tic disorder: Very limited data available: Children and Adolescents 7 to 16 years: Oral: Initial dose: 5 mg/day for 3 days then using twice-daily dosing, titrate dose as tolerated up to 40 mg/day divided twice daily. Dosing is based on a double-blind, placebo-controlled pilot study (n=28); mean daily dose at the end of trial: 28.2 ± 9.6 mg/day (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Oral: There are no pediatric-specific recommendations; based on experience in adult patients, no adjustment may be necessary.

IM: There are no pediatric-specific recommendations; cyclodextrin, an excipient in the IM formulation, is cleared by renal filtration; use with caution.

Ziprasidone is not removed by hemodialysis.

Dosing: Hepatic Impairment: Pediatric

No dosage adjustment is recommended; however, drug undergoes extensive hepatic metabolism and systemic exposure may be increased. Use with caution.

Adverse Reactions (Significant): Considerations
CNS depression

CNS depressive symptoms, including drowsiness and somnolence have been reported with ziprasidone and may cause nonadherence and impair physical and/or mental abilities resulting in subsequent falling and fracture, particularly in older adults.

Mechanism: Dose-related, related to the pharmacologic action; somnolence is believed to be due to histamine-1 receptor antagonism leading to potential CNS depressant effects (Ref).

Risk factors:

• Specific antipsychotic (ziprasidone is considered to be moderately sedating at usual therapeutic doses in comparison with other antipsychotics) (Ref)

• High doses (Ref)

• Concurrent administration with other CNS depressants (eg, benzodiazepines, antihistamines) (Ref)

Dyslipidemia

Antipsychotics are associated with dyslipidemia in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Of the second-generation antipsychotics, ziprasidone is associated with a low risk of causing lipid abnormalities; however, hypercholesterolemia has been observed (Ref).

Onset: Intermediate; increases in cholesterol have been reported within 2 to 4 weeks of antipsychotic initiation (Ref).

Risk factors:

• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population, primarily due to cardiovascular disease (Ref)

Extrapyramidal symptoms

Ziprasidone may cause extrapyramidal reaction, also known as drug-induced movement disorders. Antipsychotics cause four main extrapyramidal symptoms (EPS): Acute dystonia, drug-induced parkinsonism, akathisia, and tardive dyskinesia (Ref). EPS presenting as dysphagia, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (Ref).

Mechanism: EPS: Dose-related; due to antagonism of dopaminergic D2 receptors in nigrostriatal pathways (Ref). Tardive dyskinesia: Time-related (delayed); results from chronic exposure to D2 receptor antagonists leading to up-regulation of these receptors over time (Ref).

Onset:

Antipsychotics in general:

Acute dystonia: Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (Ref).

Drug-induced parkinsonism: Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (Ref).

Akathisia: Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases, and within 3 months in 90% of cases (Ref).

Tardive dyskinesia: Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a D2 receptor antagonist and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization, and then a chronic waxing and waning of symptoms (Ref).

Esophageal dysfunction (associated with EPS): Varied; ranges from weeks to months following initiation (Ref).

Risk factors:

EPS (in general):

• Prior history of EPS (Ref)

• Higher doses (Ref)

• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (Ref)

• Specific antipsychotic: Ziprasidone is usually associated with a low propensity to cause EPS compared to other antipsychotics (Ref)

Acute dystonia:

• Males (Ref)

• Young age (Ref)

Drug-induced parkinsonism:

• Females (Ref)

• Older patients (Ref)

Akathisia:

• Higher antipsychotic dosages (Ref)

• Polypharmacy (Ref)

• Mood disorders (Ref)

• Females (Ref)

• Older patients (Ref)

Tardive dyskinesia:

• Acute motor symptoms (eg, parkinsonism symptoms, Parkinson disease) (Ref)

• Age >55 years, females >55 years (Ref)

• Cognitive impairment (Ref)

• Concomitant treatment with anticholinergic medications (Ref)

• Diabetes (Ref)

• Diagnosis of schizophrenia or affective disorders (Ref)

• Females (Ref)

• Greater total antipsychotic exposure (especially first-generation antipsychotics) (Ref)

• History of EPS (Ref)

• Poor treatment response (Ref)

• Substance misuse or dependence (Ref)

• Race (White or African descent). Note: Although early literature supported race as a potential risk factor for tardive dyskinesia (Ref), newer studies have challenged this assertion (Ref).

Esophageal dysfunction (associated with EPS):

• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (Ref)

• Adults >75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (Ref)

Hematologic abnormalities

Agranulocytosis, leukopenia, and thrombocytopenia have been reported with ziprasidone. Neutropenia has been reported with other second-generation antipsychotics (Ref).

Onset: Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (Ref).

Risk factors:

• History of drug-induced leukopenia/neutropenia and preexisting low white blood cell count/absolute neutrophil count

• Older adults (Ref)

Hyperglycemia

Antipsychotics are associated with hyperglycemia in adult and pediatric patients, to varying degrees, which is a component of the metabolic syndrome observed with the pharmacologic class (Ref). Ziprasidone is associated with a low risk of causing metabolic alterations in adult patients; however, glycemic abnormalities ranging from hyperglycemia to diabetes mellitus, and hyperglycemic hyperosmolar syndrome have been observed rarely (Ref).

Onset: Varied; with antipsychotics in general, new-onset diabetes has been observed within the first 3 months to a median onset of 3.9 years (Ref).

Risk factors:

Antipsychotics in general:

• African-American race (Ref)

• Males (Ref)

• Age <35 years (Ref)

• Preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (Ref)

• Exposure to other agents that also increase the risk of hyperglycemia (Ref)

• Specific antipsychotic: Ziprasidone is associated with a low to moderate risk of metabolic disturbances (Ref).

Hyperprolactinemia

Ziprasidone is typically associated with a lower risk of causing significant effects on prolactin compared to other second-generation antipsychotics with a higher risk (such as risperidone), although there are case reports of hyperprolactinemia in adult and pediatric patients (Ref). Hyperprolactinemia may lead to gynecomastia, galactorrhea not associated with childbirth, amenorrhea, sexual disorder, and infertility (Ref). Although long-term effects of elevated prolactin levels have not been fully evaluated, some studies suggest a possible association between hyperprolactinemia and an increased risk for breast and/or pituitary tumors and osteopenia/osteoporosis (Ref).

Mechanism: Related to the pharmacologic action; antagonism of dopamine D2 receptors in the tuberoinfundibular dopaminergic pathway causes disinhibition of prolactin release resulting in hyperprolactinemia (Ref).

Onset: Varied; typically within a few weeks following initiation, but may also arise after long-term, stable use (Ref).

Risk factors:

• Specific antipsychotic: Ziprasidone is considered a prolactin-sparing antipsychotic with a low risk for hyperprolactinemia (Ref)

• Higher doses (Ref)

• Females (particularly those of reproductive age) (Ref)

Hypersensitivity reactions

Hypersensitivity reaction, including angioedema, skin rash, and urticaria, have been reported with ziprasidone. Drug reaction with eosinophilia and systemic symptoms (DRESS) and severe cutaneous adverse reactions (SCARs) (ie, Stevens-Johnson syndrome) have also been reported.

Mechanism: Hypersensitivity reactions: Delayed hypersensitivity reactions, including SCARs, are T-cell mediated (Ref).

Onset: Varied; in one case report, systemic hypersensitivity reaction with pruritic skin rash occurred 3 weeks following ziprasidone initiation; symptoms recurred 2 days after ziprasidone rechallenge (Ref). In another case report, urticaria and angioedema occurred 27 days and 30 days, respectively, following ziprasidone initiation (Ref).

Mortality in older adults

Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to those treated with placebo. Although the causes of death were varied, most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (Ref). In addition, an increased incidence of cerebrovascular effects, including fatalities, have been reported in placebo-controlled trials of other second-generation antipsychotics in older adults with dementia-related psychosis. Of note, ziprasidone is not approved for the treatment of dementia-related psychosis.

Mechanism: Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (Ref).

Risk factors:

Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)

Higher antipsychotic dosage (Ref)

Neuroleptic malignant syndrome

All antipsychotics have been associated with neuroleptic malignant syndrome (NMS), although the incidence is lower with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with ziprasidone, including monotherapy (Ref).

Mechanism: Idiosyncratic; possibly due to a reduction in CNS dopaminergic tone, along with dysregulation of autonomic nervous system activity (Ref).

Onset: Varied; in general, most patients develop NMS within 2 weeks of antipsychotic initiation or dose increase. In some patients, prodromal symptoms emerge within an hour of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (Ref). However, NMS may also occur months after stable antipsychotic therapy (Ref).

Risk factors:

Antipsychotics in general:

• Males (twice as likely to develop NMS compared to females) (Ref)

• Dehydration (Ref)

• High-dose antipsychotic treatment (Ref)

• Concomitant lithium or benzodiazepine (potential risk factors) (Ref)

• Catatonia (Ref)

• Polypharmacy (Ref)

• Pharmacokinetic interactions (Ref)

• IM administration (Ref)

• Rapid dosage escalation (Ref)

• Psychomotor agitation (Ref)

Orthostatic hypotension

Ziprasidone may cause orthostatic hypotension (although at a lower prevalence compared to first-generation antipsychotics and certain second-generation antipsychotics, such as clozapine, risperidone, and quetiapine) and accompanying tachycardia, dizziness, and syncope in adults (Ref). Orthostatic hypotension may result in subsequent falls and fractures, particularly in older adults (Ref).

Mechanism: Related to pharmacologic action; orthostatic hypotension is thought to be due to alpha-1 adrenergic receptor antagonism (Ref).

Onset: Rapid; per manufacturer's labeling, orthostatic hypotension is most common during initial dose titration.

Risk factors:

• Known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities)

• Cerebrovascular disease

• Conditions which would predispose patients to hypotension (dehydration, hypovolemia, treatment with antihypertensive agents)

• Older adults

QT prolongation

Ziprasidone is associated with prolonged QT interval on ECG in adult and pediatric patients, including reports of torsades de pointes (TdP), predominantly in the setting of multiple risk factors (Ref). Of the second-generation antipsychotics, ziprasidone is associated with a higher risk of QTc prolongation (Ref). In clinical trials, the average increase in QTc following oral ziprasidone was approximately 5 to 23 ms (Ref).

Mechanism: Dose-related; ziprasidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current (Ref), although other mechanisms may also be involved (Ref).

Risk factors:

Drug-induced QTc prolongation/TdP (in general):

• Females (Ref)

• Age >65 years (Ref)

• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (Ref)

• History of drug-induced TdP (Ref)

• Genetic defects of cardiac ion channels (Ref)

• Congenital long QT syndrome (Ref)

• Baseline QTc interval prolongation (eg, >500 msec) or lengthening of the QTc by ≥60 msec (Ref)

• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (Ref)

• Bradycardia (Ref)

• Hepatic impairment (Ref)

• Kidney impairment (Ref)

• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (Ref)

• Substance use (Ref)

Temperature dysregulation

Antipsychotics may impair the body’s ability to regulate core body temperature, which may contribute to an elevation in core body temperature during predisposing conditions such as strenuous exercise or dehydration. Hypothermia has been reported with ziprasidone (Ref).

Mechanism: Non–dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D2 antagonism may cause an increase in body temperature, while 5-HT2A (serotonin) receptor antagonism may cause a decrease in body temperature. Of note, ziprasidone has stronger affinity for 5-HT2A receptors than for D2 receptors, suggesting that it is more likely to cause a reduction in body temperature than an increase. In addition, antagonism of peripheral alpha-1 adrenergic receptors has also been suggested as a factor in the hypothermic effect by inhibiting peripheral responses to cooling (Ref).

Onset: Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (Ref).

Risk factors:

Heat stroke:

• Psychiatric illness (regardless of medication use) (Ref)

• Dehydration (Ref)

• Strenuous exercise (Ref)

• Heat exposure (Ref)

• Concomitant medications possessing anticholinergic effects (Ref)

Hypothermia:

• In general, predisposing risk factors include: Older adults, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis benzodiazepine use, alcohol intoxication, kidney or liver failure (Ref)

• Schizophrenia (regardless of antipsychotic use) (Ref)

Weight gain

Ziprasidone is associated with significant weight gain (increase of ≥7% from baseline) in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class.

Mechanism: Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (Ref).

Onset: Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term (Ref).

Risk factors:

• Family history of obesity (Ref)

• Parental BMI (Ref)

• Children and adolescents (Ref)

• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of >5% in the first month has been observed as the best predictor for significant long-term weight gain (Ref)

• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (Ref)

• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (Ref)

• Specific antipsychotic: Ziprasidone is considered to have a low propensity for causing weight gain; olanzapine and clozapine are associated with a high risk (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequencies represent oral administration in adults unless otherwise indicated.

>10%:

Endocrine & metabolic: Weight gain (4% to 16%) (table 1)

Ziprasidone: Adverse Reaction: Weight Gain

Drug (Ziprasidone)

Placebo

Dose

Dosage Form

Indication

Number of Patients (Ziprasidone)

Number of Patients (Placebo)

4%

2%

60 to 80 mg twice daily

Oral capsules

Bipolar disorder

388

451

2%

2%

20 to 40 mg twice daily

Oral capsules

Bipolar disorder

295

451

16%

4%

80 mg twice daily

Oral capsules

Schizophrenia

97

227

11%

4%

100 mg twice daily

Oral capsules

Schizophrenia

74

227

10%

4%

40 mg twice daily

Oral capsules

Schizophrenia

135

227

9%

4%

20 mg twice daily

Oral capsules

Schizophrenia

167

227

7%

4%

60 mg twice daily

Oral capsules

Schizophrenia

109

227

Gastrointestinal: Nausea (IM and oral: 8% to 12%)

Nervous system: Dizziness (IM and oral: 3% to 16%) (table 2), drowsiness (IM: 8% to 20%; oral: 14% to 31%) (table 3), extrapyramidal reaction (14% to 31%) (table 4), headache (IM and oral: 5% to 18%)

Ziprasidone: Adverse Reaction: Dizziness

Drug (Ziprasidone)

Placebo

Dose

Dosage Form

Indication

Number of Patients (Ziprasidone)

Number of Patients (Placebo)

10%

N/A

20 mg

IM

Agitation in schizophrenic patients

41

N/A

3%

N/A

10 mg

IM

Agitation in schizophrenic patients

63

N/A

16%

7%

40 to 80 mg twice daily

Oral capsules

Manic and mixed episodes associated with bipolar disorder

279

136

8%

6%

N/A

Oral capsules

Schizophrenia

702

273

Ziprasidone: Adverse Reaction: Drowsiness

Drug (Ziprasidone)

Placebo

Dose

Dosage Form

Indication

Number of Patients (Ziprasidone)

Number of Patients (Placebo)

20%

N/A

20 mg

IM

Agitation in schizophrenic patients

41

N/A

8%

N/A

10 mg

IM

Agitation in schizophrenic patients

63

N/A

31%

12%

40 to 80 mg twice daily

Oral capsules

Manic and mixed episodes associated with bipolar disorder

279

136

14%

7%

N/A

Oral capsules

Schizophrenia

702

273

Ziprasidone: Adverse Reaction: Extrapyramidal Reaction

Drug (Ziprasidone)

Placebo

Dose

Dosage Form

Indication

Number of Patients (Ziprasidone)

Number of Patients (Placebo)

31%

12%

40 to 80 mg twice daily

Oral capsules

Manic and mixed episodes associated with bipolar disorder

279

136

14%

8%

N/A

Oral capsules

Schizophrenia

702

273

1% to 10%:

Cardiovascular: Bradycardia (IM and oral: ≤2%), chest pain (3%), hypertension (3%), orthostatic hypotension (IM: 5%, oral: ≥1%), tachycardia (2%) (table 5)

Ziprasidone: Adverse Reaction: Tachycardia

Drug (Ziprasidone)

Placebo

Dosage Form

Indication

Number of Patients (Ziprasidone)

Number of Patients (Placebo)

2%

1%

Oral capsules

Schizophrenia

702

273

Dermatologic: Diaphoresis (IM: 2%), fungal dermatitis (2%), furunculosis (IM: 2%), skin photosensitivity (≥1%), skin rash (4% to 5%)

Gastrointestinal: Abdominal pain (IM: 2%; oral: ≥1%), anorexia (IM and oral: 2%), constipation (IM: 2%; oral: 9%), diarrhea (IM and oral: 3% to 5%), dyspepsia (IM and oral: 2% to 8%), dysphagia (2%) (table 6), rectal hemorrhage (IM and oral: ≤2%), sialorrhea (4%), vomiting (IM and oral: 3% to 5%), xerostomia (4% to 5%)

Ziprasidone: Adverse Reaction: Dysphagia

Drug (Ziprasidone)

Placebo

Dose

Dosage Form

Indication

Number of Patients (Ziprasidone)

Number of Patients (Placebo)

2%

0%

40 to 80 mg twice daily

Oral capsules

Manic and mixed episodes associated with bipolar disorder

279

136

Genitourinary: Dysmenorrhea (IM: 2%)

Hypersensitivity: Facial edema (≥1%), tongue edema (3%)

Local: Pain at injection site (IM: 7% to 8%)

Nervous system: Abnormal gait (≥1%), agitation (IM: 2%; oral: ≥1%), akathisia (IM: 2%; oral: 8% to 10%) (table 7), akinesia (≥1%), amnesia (≥1%), anxiety (5%), asthenia (5% to 6%), ataxia (≥1%), buccoglossal syndrome (≥1%), chills (≥1%), choreoathetosis (≥1%), cogwheel rigidity (≥1%), confusion (≥1%), delirium (≥1%), dysarthria (≥1%), falling (≥1%), hostility (≥1%), hypertonia (≥1%), hypoesthesia (2%), hypothermia (≥1%), hypotonia (≥1%), neuropathy (≥1%), paresthesia (IM: 2%; oral: ≥1%), personality disorder (IM: 2%), speech disturbance (IM and oral: 2%), tremor (≥1%), twitching (≥1%), vertigo (≥1%), withdrawal syndrome (≥1%)

Ziprasidone: Adverse Reaction: Akathisia

Drug (Ziprasidone)

Placebo

Dose

Dosage Form

Indication

Number of Patients (Ziprasidone)

Number of Patients (Placebo)

2%

N/A

10 mg

IM

Agitation in schizophrenic patients

63

N/A

10%

5%

40 to 80 mg twice daily

Oral capsules

Manic and mixed episodes associated with bipolar disorder

279

136

8%

7%

N/A

Oral capsules

Schizophrenia

702

273

Neuromuscular & skeletal: Dyskinesia (≥1%), dystonia (≥1%), hyperkinetic muscle activity (≥1%), hypokinesia (≥1%), myalgia (2%)

Ophthalmic: Diplopia (≥1%), oculogyric crisis (≥1%), visual disturbance (3% to 6%)

Renal: Flank pain (≥1%)

Respiratory: Dyspnea (2%), flu-like symptoms (≥1%), increased cough (3%), pharyngitis (3%), respiratory tract infection (8%), rhinitis (4%)

Miscellaneous: Accidental injury (4%), fever (≥1%)

<1%:

Cardiovascular: Angina pectoris, atrial fibrillation, bundle branch block, cardiomegaly, deep vein thrombophlebitis, first-degree atrioventricular block, myocarditis, peripheral edema, phlebitis, pulmonary embolism, syncope, thrombophlebitis

Dermatologic: Alopecia, contact dermatitis, ecchymoses, eczema, exfoliative dermatitis, maculopapular rash, urticaria, vesicobullous dermatitis

Endocrine & metabolic: Albuminuria, amenorrhea, decreased glucose tolerance, dehydration, gynecomastia, heavy menstrual bleeding, hyperchloremia, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hyperthyroidism, hyperuricemia, hypocalcemia, hypochloremia, hypocholesterolemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypothyroidism, increased lactate dehydrogenase, increased thirst, ketosis, respiratory alkalosis, thyroiditis

Gastrointestinal: Fecal impaction, gingival hemorrhage, hematemesis, melena, oral leukoplakia, oral paresthesia

Genitourinary: Anorgasmia, ejaculatory disorder, erectile dysfunction, female sexual disorder, glycosuria, hematuria, lactation, male sexual disorder, nocturia, oliguria, polyuria, urinary retention, uterine hemorrhage, vaginal hemorrhage

Hematologic & oncologic: Anemia, basophilia, eosinophilia, hemophthalmos, hypochromic anemia, hypoproteinemia, leukocytosis, leukopenia, lymphadenopathy, lymphedema, lymphocytosis, monocytosis, polycythemia, thrombocytopenia, thrombocytosis

Hepatic: Cholestatic jaundice, hepatitis, hepatomegaly, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum transaminases, jaundice, liver steatosis

Nervous system: Cerebral infarction, cerebrovascular accident, hyperreflexia, myoclonus, opisthotonus, paralysis, seizure, trismus

Neuromuscular & skeletal: Gout, increased creatine phosphokinase in blood specimen, myopathy, tenosynovitis, torticollis

Ophthalmic: Blepharitis, cataract, conjunctivitis, dry eye syndrome, keratitis, keratoconjunctivitis, nystagmus disorder, photophobia, visual field defect

Otic: Tinnitus

Renal: Increased blood urea nitrogen, increased serum creatinine

Respiratory: Epistaxis, hemoptysis, laryngismus, pneumonia

Frequency not defined: Neuromuscular & skeletal: Arthralgia

Postmarketing:

Cardiovascular: Prolonged QT interval on ECG (Atkinson 2022, Blair 2004, Camm 2012, Findling 2022), torsades de pointes (Heinrich 2006)

Dermatologic: Stevens-Johnson syndrome

Endocrine & metabolic: Diabetes mellitus (Greenberg 2007), galactorrhea not associated with childbirth (Raza 2010), hyperglycemic hyperosmolar syndrome (Létourneau 2011), hyperprolactinemia (Lusskin 2004)

Genitourinary: Priapism (Karamustafalioglu 2013), urinary incontinence

Hematologic & oncologic: Agranulocytosis (Montgomery 2006)

Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Chan 2015), hypersensitivity reaction (including allergic dermatitis, angioedema, orofacial edema) (Akkaya 2007), swollen tongue

Nervous system: Facial nerve paralysis, hypomania, insomnia, mania, neuroleptic malignant syndrome (Ozen 2007), serotonin syndrome (Lin 2010)

Neuromuscular & skeletal: Tardive dyskinesia (Ananth 2004)

Respiratory: Sleep apnea (obstructive) (Shirani 2011)

Contraindications

Hypersensitivity to ziprasidone or any component of the formulation; history of (or current) prolonged QT; congenital long QT syndrome; recent myocardial infarction; uncompensated heart failure; concurrent use of other QTc-prolonging agents including arsenic trioxide, chlorpromazine, class Ia antiarrhythmics (eg, disopyramide, quinidine, procainamide), class III antiarrhythmics (eg, amiodarone, dofetilide, ibutilide, sotalol), dolasetron, droperidol, gatifloxacin, halofantrine, levomethadyl, mefloquine, mesoridazine, moxifloxacin, pentamidine, pimozide, probucol, sparfloxacin, tacrolimus, and thioridazine

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.

Disease-related concerns:

• Cardiovascular disease: Use is contraindicated in patients with recent acute myocardial infarction (MI), QT prolongation, or uncompensated heart failure. Avoid use in patients with a history of cardiac arrhythmias; use with caution in patients with history of MI or unstable heart disease.

• Hepatic impairment: Use with caution in patients with hepatic disease or impairment.

• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.

Dosage form specific issues:

• Intramuscular formulation: Use the intramuscular formulation with caution in patients with renal impairment; formulation contains cyclodextrin, an excipient which may accumulate in renal insufficiency, although the clinical significance of this finding is uncertain (Luke 2010).

Other warnings/precautions:

• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).

Warnings: Additional Pediatric Considerations

In June 2009, an FDA advisory panel advised that ziprasidone is effective in patients 10 to 17 years of age for the treatment of mixed and manic episodes of bipolar disorder, but did not conclude that it was safe due to a large number of subjects lost to follow-up and ambiguity within QTc prolongation data. Since then, prescribing of ziprasidone has decreased similarly for pediatric and adult patients (Wang 2016).

Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients. Medication therapy for pediatric patients with bipolar disorder is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions. A systematic review and meta-analysis of trials (n=2,158; age range: 8 to 19 years old) reported inferior efficacy of ziprasidone compared to other agents (aripiprazole, asenapine, paliperidone, risperidone, quetiapine, olanzapine, molindone) for youth with early-onset schizophrenia (Pagsberg 2017). Another systematic review evaluating the effect and safety of atypical antipsychotics for treatment of disruptive behavior disorders in children and youths noted a lack of evidence to support ziprasidone in children ≥5 years and youth and no evidence for children <5 years of age (Loy 2017).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral, as hydrochloride:

Geodon: 20 mg, 40 mg, 60 mg, 80 mg

Generic: 20 mg, 40 mg, 60 mg, 80 mg

Solution Reconstituted, Intramuscular, as mesylate [strength expressed as base]:

Generic: 20 mg (1 ea)

Solution Reconstituted, Intramuscular, as mesylate [strength expressed as base, preservative free]:

Geodon: 20 mg (1 ea)

Generic: 20 mg (1 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Geodon Oral)

20 mg (per each): $28.51

40 mg (per each): $28.51

60 mg (per each): $34.60

80 mg (per each): $34.60

Capsules (Ziprasidone HCl Oral)

20 mg (per each): $8.00 - $8.96

40 mg (per each): $8.00 - $8.96

60 mg (per each): $9.83 - $10.88

80 mg (per each): $9.83 - $10.88

Solution (reconstituted) (Geodon Intramuscular)

20 mg (per each): $73.63

Solution (reconstituted) (Ziprasidone Mesylate Intramuscular)

20 mg (per each): $23.89 - $56.40

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral, as hydrochloride:

Zeldox: 20 mg, 40 mg, 60 mg, 80 mg

Generic: 20 mg, 40 mg, 60 mg, 80 mg

Administration: Adult

Oral: Administer capsule with food (≥500 calories) (Ref). Swallow capsule whole; do not open, crush, or chew capsules.

Injection: For IM administration only.

Administration: Pediatric

Oral: Administer capsule with food (in adults, ≥500 calories) (Ref). Swallow capsule whole; do not open, crush, or chew capsules.

Parenteral: For IM use only; do not administer IV.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 3]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Use: Labeled Indications

Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia, bipolar disorder), substance intoxications, or other organic causes (IM only): Treatment of acute agitation in patients with schizophrenia for whom treatment with ziprasidone is appropriate and who need IM antipsychotic medication for rapid control of agitation. May be used off label for the treatment of acute agitation associated with bipolar disorder (CANMAT [Yatham 2018]) and substance intoxication (Wilson 2012).

Bipolar disorder: Monotherapy for the acute treatment of manic episodes with or without mixed features associated with bipolar disorder; for the maintenance treatment of bipolar disorder (manic or mixed episodes) as monotherapy (off label) or as an adjunct to lithium or valproate. May be used off label for the treatment of hypomania (CANMAT [Yatham 2018]).

Schizophrenia: Treatment of schizophrenia.

Use: Off-Label: Adult

Delirium in the ICU, hyperactive, treatment; Delusional infestation (delusional parasitosis); Major depressive disorder, treatment resistant (unipolar, nonpsychotic)

Medication Safety Issues
Sound-alike/look-alike issues:

Ziprasidone may be confused with TraZODone

Older Adult: High-Risk Medication:

Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Risk C: Monitor therapy

Amiodarone: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk. Risk D: Consider therapy modification

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin). Risk D: Consider therapy modification

ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Arsenic Trioxide: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Arsenic Trioxide. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Astemizole: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Astemizole. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Bedaquiline: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Bedaquiline. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor therapy

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents. Risk X: Avoid combination

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor therapy

Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents. Risk X: Avoid combination

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

ChlorproMAZINE: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of ChlorproMAZINE. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Cisapride: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Cisapride. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. Risk X: Avoid combination

Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. Risk X: Avoid combination

Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Ziprasidone. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ziprasidone. Risk C: Monitor therapy

Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Delamanid: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Delamanid. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased. Risk C: Monitor therapy

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. Risk X: Avoid combination

Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents. Risk C: Monitor therapy

Doxepin-Containing Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. Risk C: Monitor therapy

Dronedarone: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Dronedarone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

DroPERidol: May enhance the QTc-prolonging effect of Ziprasidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk X: Avoid combination

Encorafenib: May enhance the QTc-prolonging effect of Ziprasidone. Encorafenib may decrease the serum concentration of Ziprasidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and decreased ziprasidone concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Risk X: Avoid combination

Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Risk X: Avoid combination

Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Fluconazole: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluconazole. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. Risk X: Avoid combination

FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents. Risk C: Monitor therapy

Gemifloxacin: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias. Risk D: Consider therapy modification

Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. Risk C: Monitor therapy

Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Haloperidol: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Haloperidol. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents. Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Iboga: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider therapy modification

Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider therapy modification

Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider therapy modification

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Levofloxacin-Containing Products (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Levoketoconazole: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Levoketoconazole. Risk X: Avoid combination

Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine. Risk C: Monitor therapy

Lofexidine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Lofexidine. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine. Management: Consider alternatives to one of these agents when possible. While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged. Risk D: Consider therapy modification

Methadone: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents. Risk X: Avoid combination

MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased. Risk C: Monitor therapy

Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). Risk X: Avoid combination

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. Risk X: Avoid combination

OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Ondansetron: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Pacritinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Papaverine: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Papaverine. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

PAZOPanib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib. Risk X: Avoid combination

Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk X: Avoid combination

Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. Risk X: Avoid combination

Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents. Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended. Risk X: Avoid combination

Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor therapy

Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. Risk X: Avoid combination

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Propafenone: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Highest Risk). Risk X: Avoid combination

QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. Risk X: Avoid combination

Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. Risk C: Monitor therapy

QuiNINE: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of QuiNINE. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. Risk X: Avoid combination

RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Rivastigmine: May enhance the neurotoxic (central) effect of Antipsychotic Agents. Risk C: Monitor therapy

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Risk C: Monitor therapy

Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Risk X: Avoid combination

Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. Risk C: Monitor therapy

Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. Risk X: Avoid combination

Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. Risk X: Avoid combination

SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Terbutaline: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Terfenadine: May enhance the QTc-prolonging effect of Ziprasidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased. Risk C: Monitor therapy

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. Risk X: Avoid combination

Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider therapy modification

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. Risk C: Monitor therapy

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Food Interactions

Administration with a meal containing at least 500 calories increases serum levels ~80%. Management: Administer with a meal containing at least 500 calories (Lincoln 2010).

Reproductive Considerations

Ziprasidone may cause hyperprolactinemia, which may cause a reversible reduction of reproductive function in females.

If treatment is needed in a woman planning a pregnancy, use of an agent other than ziprasidone may be preferred (Grunze 2018; Larsen 2015).

Pregnancy Considerations

Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.

The American College of Obstetricians and Gynecologists recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy are limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is initiated during pregnancy, use of an agent other than ziprasidone may be preferred (Grunze 2018; Larsen 2015).

Health care providers are encouraged to enroll women 18 to 45 years of age exposed to ziprasidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or https://www.womensmentalhealth.org/pregnancyregistry).

Breastfeeding Considerations

Ziprasidone is present in breast milk (Schlotterbeck 2009).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Monitor infants exposed to ziprasidone via breast milk for excess sedation, irritability, poor feeding, and extrapyramidal symptoms. Until additional information is available, use of agents other than ziprasidone in breastfeeding women may be preferred (Larsen 2015).

Dietary Considerations

Capsule: Take with food.

Monitoring Parameters

Frequency of Antipsychotic Monitoringa,b

Monitoring parameter

Frequency of monitoring

Comments

a For all monitoring parameters, it is appropriate for check at baseline and when clinically relevant (based on symptoms or suspected adverse reactions) in addition to the timeline.

b ADA 2004; APA [Keepers 2020]; De Hert 2011; Gugger 2011; manufacturer's labeling.

c Cardiac risk factors include congenital long QT syndrome, structural or functional cardiac disease, bradycardia, family history of sudden cardiac death.

d Risk factors for extrapyramidal symptoms (EPS) include prior history of EPS, high doses of antipsychotics, young age (children and adolescents at higher risk than adults), and dopaminergic affinity of individual antipsychotic.

e Risk factors for tardive dyskinesia include age >55 years; females; White or African ethnicity; presence of a mood disorder, intellectual disability, or CNS injury; past or current EPS.

Adherence

Every visit

Blood chemistries (electrolytes, renal function, liver function, TSH)

Annually

Correct electrolyte imbalances (hypokalemia) prior to administration; may prolong QT interval

CBC

As clinically indicated

Check frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia

ECG

As clinically indicated

Check after significant dose increase or new QTc prolonging medication if there are cardiac risk factorsc

Extrapyramidal symptoms

Every visit; 4 weeks after initiation and dose change; annually. Use a formalized rating scale at least annually or every 6 months if high risk.d

Fall risk

Every visit

Fasting plasma glucose/HbA1c

12 weeks after initiation and dose change; annually

Check more frequently than annually if abnormal. Follow diabetes guidelines.

Lipid panel

12 weeks after initiation and dose change; annually

Check more frequently than annually if abnormal. Follow lipid guidelines.

Mental status and alertness

Every visit

Metabolic syndrome history

Annually

Evaluate for personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease

Prolactin

Ask about symptoms at every visit until dose is stable. Check prolactin level if symptoms are reported.

Hyperprolactinemia symptoms: Changes in menstruation, libido, gynecomastia, development of galactorrhea, and erectile and ejaculatory function

Tardive dyskinesia

Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high risk.e

Vital signs (BP, orthostatics, temperature, pulse, signs of infection)

Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change.

Weight/Height/BMI

8 and 12 weeks after initiation and dose change; quarterly

Consider monitoring waist circumference at baseline and annually, especially in patients with or at risk for metabolic syndrome.

Consider changing antipsychotic if BMI increases by ≥1 unit.

Some experts recommend checking weight and height at every visit.

Reference Range

Timing of serum samples: Draw trough just before next dose (Hiemke 2018).

Therapeutic reference range: 50 to 200 ng/mL (SI: 127.5 to 510 nmol/L) (Hiemke 2018). Note: Dosing should be based on therapeutic response as opposed to serum concentrations; however, therapeutic drug monitoring can be used to confirm adherence (APA [Keepers 2020]).

Laboratory alert level: 400 ng/mL (SI: 1,020 nmol/L) (Hiemke 2018).

Mechanism of Action

Ziprasidone is a benzylisothiazolylpiperazine antipsychotic. The exact mechanism of action is unknown. However, in vitro radioligand studies show that ziprasidone has high affinity for D2, D3, 5-HT2A, 5-HT1A, 5-HT2C, 5-HT1D, and alpha1-adrenergic; moderate affinity for histamine H1 receptors; and no appreciable affinity for alpha2-adrenergic receptors, beta-adrenergic, 5-HT3, 5-HT4, cholinergic, mu, sigma, or benzodiazepine receptors. Ziprasidone functions as an antagonist at the D2, 5-HT2A, and 5-HT1D receptors and as an agonist at the 5-HT1A receptor. Ziprasidone moderately inhibits the reuptake of serotonin and norepinephrine.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action:

Agitation: IM: Initial effects within 15 minutes; adequate sedation within 30 minutes (Martel 2005).

Bipolar disorder, acute mania: Oral: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).

Major depressive disorder, unipolar: Oral: Initial effects may be observed within 1 week with continued improvements over 6 to 12 weeks (Wen 2014).

Schizophrenia: Oral: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).

Absorption: Well absorbed; administration with 500 calorie meals increases serum levels ~80% (Lincoln 2010).

Distribution: Vd: 1.5 L/kg.

Protein binding: >99%, primarily to albumin and alpha-1 acid glycoprotein.

Metabolism: Extensively hepatic, primarily chemical and enzymatic reductions via glutathione and aldehyde oxidase, respectively; less than 1/3 of total metabolism via CYP3A4 and CYP1A2 (minor).

Bioavailability: Oral (with food): 60%; IM: 100%.

Half-life elimination:

Oral: Mean terminal half-life:

Children: Mean: 3.3 to 4.1 hours (Sallee 2006).

Adults: 7 hours.

IM: Mean half-life: 2 to 5 hours.

Time to peak:

Oral: Children: Mean: 5 to 5.5 hours (Sallee 2006); Adults: 6 to 8 hours.

IM: ≤60 minutes.

Excretion: Feces (~66%; <4% of total dose as unchanged drug); urine (~20%; <1% of total dose as unchanged drug).

Clearance:

Children: Mean: 11.5 to 13.1 mL/minute/kg (Sallee 2006).

Adults: Mean: 7.5 mL/minute/kg.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Increases the AUC of ziprasidone.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Zeldox;
  • (AR) Argentina: Zeldox;
  • (AT) Austria: Zeldox | Ziprasidon actavis | Ziprasidon Krka | Ziprasidon Pfizer | Ziprasidon Ratiopharm | Ziprasidon Stada | Ziprasidon viatris;
  • (AU) Australia: Apo ziprasidone | Zeldox | Ziprasidone gh | Ziprox;
  • (BD) Bangladesh: Zipsydon;
  • (BG) Bulgaria: Zeldox | Zipwell;
  • (BR) Brazil: Cloridrato de ziprasidona | Cloridrato de ziprasidona monoidratado | Geodon | Lfm ziprasidona;
  • (CL) Chile: Zeldox;
  • (CN) China: Si bei ge | Zeldox;
  • (CO) Colombia: Geodon;
  • (CZ) Czech Republic: Zeldox | Ziprasidon Mylan | Zypsilan;
  • (DE) Germany: Zeldox | Ziprasidon 1A Pharma | Ziprasidon abz | Ziprasidon actavis | Ziprasidon AL | Ziprasidon Aurobindo | Ziprasidon Beta | Ziprasidon Hexal | Ziprasidon Hormosan | Ziprasidon Mylan | Ziprasidon Neuraxpharm | Ziprasidon Pfizer | Ziprasidon puren | Ziprasidon Ratiopharm | Ziprasidon Stada | Ziprasidone stada | Zipsilan;
  • (DK) Denmark: Zeldox;
  • (DO) Dominican Republic: Geodon;
  • (EC) Ecuador: Geodon;
  • (EE) Estonia: Ypsila | Zeldox;
  • (EG) Egypt: Zeldox;
  • (ES) Spain: Zeldox | Ziprasidona Aurobindo | Ziprasidona aurovitas | Ziprasidona cinfa | Ziprasidona Kern | Ziprasidona Mylan | Ziprasidona normon | Ziprasidona Sandoz | Ziprasidona Stada | Zypsilan;
  • (FI) Finland: Zeldox | Ziprasidon Krka | Ziprasidon Pfizer | Ziprasidone Sandoz;
  • (GB) United Kingdom: Zeldox;
  • (GR) Greece: Geodon | Ziprasidone actavis | Ziprasidone Sandoz | Ziprasidone/Generics;
  • (HK) Hong Kong: Zeldox;
  • (HR) Croatia: Zeldox;
  • (HU) Hungary: Ypsila | Zeldox | Zipwell;
  • (IE) Ireland: Geodon;
  • (IL) Israel: Geodon;
  • (IN) India: Azona | Zipra | Zipral | Zipsydon;
  • (IT) Italy: Zeldox | Ziprasidone Sandoz;
  • (JO) Jordan: Zeldox;
  • (KR) Korea, Republic of: Zeldox;
  • (KW) Kuwait: Zeldox;
  • (LB) Lebanon: Zeldox;
  • (LT) Lithuania: Zeldox;
  • (LV) Latvia: Ypsila | Zeldox;
  • (MA) Morocco: Zeldox;
  • (MX) Mexico: Geodon | Zeldox;
  • (MY) Malaysia: Zeldox;
  • (NO) Norway: Zeldox | Ziprasidon;
  • (NZ) New Zealand: Zeldox | Zusdone;
  • (PE) Peru: Geodon | Zeldox;
  • (PH) Philippines: Zeldox;
  • (PK) Pakistan: Cara zi | Geodon | Sidone | Xepex | Zap | Zidone | Zipone | Zipra | Ziprasid | Ziprawel | Ziprawin | Ziprawrd | Zipronia | Ziprowin | Zipsilan | Zopeka | Zpras;
  • (PL) Poland: Zeldox | Zipragen | Zypsila;
  • (PR) Puerto Rico: Geodon | Ziprasidone | Ziprasidone HCL | Ziprasidone mesylate;
  • (PT) Portugal: Zeldox | Ziprasidona Actavis | Ziprasidona Aurobindo | Ziprasidona ciclum | Ziprasidona generis | Ziprasidona Mylan;
  • (QA) Qatar: Zeldox | Zeldox IM;
  • (RO) Romania: Zeldox | Zixadox | Zypsila;
  • (RU) Russian Federation: Zeldox | Zipsila;
  • (SA) Saudi Arabia: Zeldox;
  • (SE) Sweden: Geodon | Zeldox | Ziprasidon 2care4 | Ziprasidon actavis | Ziprasidon ebb | Ziprasidon paranova | Ziprasidon Stada | Ziprasidone Sandoz;
  • (SG) Singapore: Zeldox;
  • (SI) Slovenia: Zeldox;
  • (SK) Slovakia: Zeldox | Ziprasidon Mylan | Ziprasidon Zentiva | Zipwell;
  • (TH) Thailand: Zeldox;
  • (TN) Tunisia: Zeldox;
  • (TR) Turkey: Zeldox;
  • (TW) Taiwan: Geodon;
  • (UY) Uruguay: Zeldox | Zipradon;
  • (VE) Venezuela, Bolivarian Republic of: Geodon;
  • (ZA) South Africa: Geodon | Zipsid
  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.
  2. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  3. ACOG Committee on Practice Bulletins-Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation," Obstet Gynecol, 2008, 111(4):1001-20. [PubMed 18378767]
  4. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228 [PubMed 14662555]
  5. Akkaya C, Sarandol A, Aydogan K, Kirli S. Urticaria and angio-oedema due to ziprasidone. J Psychopharmacol. 2007;21(5):550-552. doi:10.1177/0269881106075273 [PubMed 17446198]
  6. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5(1):97-104. doi:10.2174/157488610789869265 [PubMed 20210726]
  7. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, “Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,” Diabetes Care, 2004, 27(2):596-601. [PubMed 14747245]
  8. Ananth J, Burgoyne KS, Niz D, Smith M. Tardive dyskinesia in 2 patients treated with ziprasidone. J Psychiatry Neurosci. 2004;29(6):467-469. [PubMed 15644988]
  9. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390 [PubMed 28861176]
  10. Atkinson S, Bachinsky M, Raiter Y, et al. 26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in children and adolescents with bipolar I disorder (most recent episode manic). J Child Adolesc Psychopharmacol. 2022;32(8):453-458. doi:10.1089/cap.2022.0030 [PubMed 36282771]
  11. Bark N. Deaths of psychiatric patients during heat waves. Psychiatr Serv. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088 [PubMed 9712220]
  12. Barzman DH, DelBello MP, Forrester JJ, et al, "A Retrospective Chart Review of Intramuscular Ziprasidone for Agitation in Children and Adolescents on Psychiatric Units: Prospective Studies Are Needed," J Child Adolesc Psychopharmacol, 2007, 17(4):503-9. [PubMed 17822344]
  13. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1-13. doi:10.1016/j.psym.2012.11.001 [PubMed 23295003]
  14. Bell JD, Hall C, Sandall J. Ziprasidone associated neuroleptic malignant syndrome. Kans J Med. 2021;14:82-83. doi:10.17161/kjm.vol1411970 [PubMed 33763185]
  15. Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0 [PubMed 25578944]
  16. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs. 2009;23(12):10031021. doi:10.2165/11530020-000000000-00000 [PubMed 19958039]
  17. Biederman J, Mick E, Spencer T, et al, "A Prospective Open-Label Treatment Trial of Ziprasidone Monotherapy in Children and Adolescents With Bipolar Disorder," Bipolar Disord, 2007, 9(8):888-94. [PubMed 18076539]
  18. Bishop JR, Rubin LH, Reilly JL, Pavuluri MN, Sweeney JA. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Ther Adv Psychopharmacol. 2012;2(3):95-102. doi:10.1177/2045125312442080 [PubMed 23983962]
  19. Blair J, Scahill L, State M, et al, "Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study," J Am Acad Child Adolesc Psychiatry, 2005, 44(1):73-9. [PubMed 15608546]
  20. Blair J, Taggart B, and Martin A, "Electrocardiographic Safety Profile and Monitoring Guidelines in Pediatric Psychopharmacology," J Neural Transm, 2004, 111(7):791-815. [PubMed 15205999]
  21. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
  22. Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F. Antipsychotics and risk of QT prolongation: a pharmacovigilance study. Psychopharmacology (Berl). 2023;240(1):199-202. doi:10.1007/s00213-022-06293-4 [PubMed 36515735]
  23. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother. 2006;40(1):139-142. doi:10.1345/aph.1G470 [PubMed 16352776]
  24. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29(1):64-73. doi:10.1592/phco.29.1.64 [PubMed 19113797]
  25. Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. Arch Intern Med. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009 [PubMed 17698676]
  26. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010;71(2):130-137. doi:10.4088/JCP.09m05482yel [PubMed 20122373]
  27. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010;71(3):338-37. doi:10.4088/JCP.08m04595gre [PubMed 20331935]
  28. Camm AJ, Karayal ON, Meltzer H, et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs. 2012;26(4):351-365. doi:10.2165/11599010-000000000-00000 [PubMed 22452529]
  29. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832 [PubMed 28146614]
  30. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry. 2003;64(8):898-906. doi:10.4088/jcp.v64n0807 [PubMed 12927004]
  31. Carnovale C, Battini V, Santoro C, et al. Umbrella review: association between antipsychotic drugs and metabolic syndrome hallmarks in children and adolescents. J Am Acad Child Adolesc Psychiatry. Published online June 23, 2023. doi:10.1016/j.jaac.2023.04.018 [PubMed 37391174]
  32. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-148. doi:10.1016/j.ncl.2010.10.002 [PubMed 21172575]
  33. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(Suppl 7):4-18. [PubMed 15151456]
  34. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013;27(7):545-572. doi:10.1007/s40263-013-0079-5 [PubMed 23821039]
  35. Chan VC, La Grenade L, Diak IL, Levin RL. US Food and Drug Administration warning about the risk of drug reaction with eosinophilia and systemic symptoms with ziprasidone. J Clin Psychiatry. 2015;76(9):e1138-e1139. doi:10.4088/JCP.15l09921 [PubMed 26455682]
  36. Contreras-Ferrer P, de Paz NM, Cejas-Mendez MR, Rodríguez-Martín M, Souto R, Bustínduy MG. Ziprasidone in the treatment of delusional parasitosis. Case Rep Dermatol. 2012;4(2):150-153. [PubMed 22807899]
  37. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):26-36. [PubMed 18533766]
  38. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, et al. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: analysis of a randomized open-label 1year study. Schizophr Res. 2017;189:134-141. doi:10.1016/j.schres.2017.01.046 [PubMed 28223031]
  39. Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case report and review of the literature. Ment Health Clin. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056 [PubMed 29955499]
  40. D'Angelo RG, Rincavage M, Tata AL, et al. Impact of an antipsychotic discontinuation bundle during transitions of care in critically ill patients. J Intensive Care Med. 2019;34(1):40-47. doi:10.1177/0885066616686741 [PubMed 28049388]
  41. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-2241. doi:10.2147/NDT.S113099 [PubMed 28883731]
  42. De Berardis D, Serroni N, Marini S, et al. Successful ziprasidone monotherapy in a case of delusional parasitosis: a one-year followup. Case Rep Psychiatry. 2013;2013:913248. doi:10.1155/2013/913248 [PubMed 23762722]
  43. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156 [PubMed 22009159]
  44. DelBello MP, Findling RL, Wang PP, et al. Efficacy and safety of ziprasidone in pediatric bipolar disorder (2008a). Presented at the 161st Annual Meeting of the American Psychiatric Association (APA); May 3-8, 2008a; Washington DC (poster).
  45. DelBello MP, Versavel M, Ice K, et al, "Tolerability of Oral Ziprasidone in Children and Adolescents With Bipolar Mania, Schizophrenia, or Schizoaffective Disorder," J Child Adolesc Psychopharmacol, 2008b, 18(5):491-9. [PubMed 18928413]
  46. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299 [PubMed 30113379]
  47. Dew RE, Hughes D. Acute dystonic reaction with moderate-dose ziprasidone. J Clin Psychopharmacol. 2004;24(5):563-564. doi:10.1097/01.jcp.0000138780.55762.36 [PubMed 15349021]
  48. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. doi:10.1155/2014/656370 [PubMed 24995318]
  49. Dominick K, Wink LK, McDougle CJ, Erickson CA. A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2015;25(5):397-401. [PubMed 26091194]
  50. Druyts E, Zoratti MJ, Toor K, et al. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a systematic review. BMC Pediatr. 2016;16(1):181. doi:10.1186/s12887-016-0710-y [PubMed 27825323]
  51. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry. 2007;68(7):1071-1077. doi:10.4088/jcp.v68n0714 [PubMed 17685744]
  52. Elbe D and Carandang CG, "Focus on Ziprasidone: A Review of Its Use in Child and Adolescent Psychiatry," J Can Acad Child Adolesc Psychiatry, 2008, 17(4):220-9. [PubMed 19018327]
  53. Fang F, Sun H, Wang Z, Ren M, Calabrese JR, Gao K. Antipsychotic drug-induced somnolence: incidence, mechanisms, and management. CNS Drugs. 2016;30(9):845-867. doi:10.1007/s40263-016-0352-5 [PubMed 27372312]
  54. Findling RL, Atkinson S, Bachinsky M, et al. Efficacy, safety, and tolerability of flexibly dosed ziprasidone in children and adolescents with mania in bipolar I disorder: a randomized placebo-controlled replication study. J Child Adolesc Psychopharmacol. 2022;32(3):143-152. doi:10.1089/cap.2021.0121 [PubMed 35394365]
  55. Findling RL, Cavuş I, Pappadopulos E, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2013;23(8):545-557. [PubMed 24111980]
  56. Findling RL, DelBello MP, Wang PP, et al, "Long-Term Safety and Tolerability of Ziprasidone in Pediatric Bipolar Disorder," Presented at the 161st Annual Meeting of the American Psychiatric Association (APA); May 3-8, 2008; Washington DC (poster). [PubMed Findling.1]
  57. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol. 2008;23(Suppl 1):27-41. doi:10.1002/hup.917 [PubMed 18098216]
  58. Fraser LA, Liu K, Naylor KL, Hwang YJ, Dixon SN, Shariff SZ, Garg AX. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450-452. doi:10.1001/jamainternmed.2014.6930 [PubMed 25581312]
  59. Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. J Clin Psychopharmacol. 2008;28(5):500-508. doi:10.1097/JCP.0b013e318185e774 [PubMed 18794644]
  60. Galling B, Roldán A, Nielsen RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73(3):247-259. doi:10.1001/jamapsychiatry.2015.2923 [PubMed 26792761]
  61. Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58-62. doi:10.4088/jcp.08m04104 [PubMed 19026256]
  62. Geodon (ziprasidone) [prescribing information]. New York, NY: Pfizer Inc; February 2022. [PubMed Geodon.1]
  63. Gibbons GM, Wein DA, Paula R. Profound hypothermia secondary to normal ziprasidone use. Am J Emerg Med. 2008;26(6):737.e1-2. doi:10.1016/j.ajem.2007.11.033 [PubMed 18606348]
  64. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006 [PubMed 17548409]
  65. Girard TD, Exline MC, Carson SS, et al; MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506-2516. doi:10.1056/NEJMoa1808217 [PubMed 30346242]
  66. Girard TD, Pandharipande PP, Carson SS, et al; MIND Trial Investigators. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med. 2010;38(2):428-437. doi:10.1097/ccm.0b013e3181c58715 [PubMed 20095068]
  67. Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. Eur Neuropsychopharmacol. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017 [PubMed 22841129]
  68. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137-177. doi:10.1111/j.1527-3458.2007.00008.x [PubMed 17627670]
  69. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19(1):2‐58. doi:10.1080/15622975.2017.1384850 [PubMed 29098925]
  70. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000 [PubMed 21790209]
  71. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003 [PubMed 15456328]
  72. Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. Environ Health Perspect. 2008;116(10):1369-1375. doi:10.1289/ehp.11339 [PubMed 18941580]
  73. Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143 [PubMed 22834451]
  74. Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.
  75. Healthy Canadians Recalls & Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/antipsycho2-eng.php. Published August 16, 2016. Accessed August 23, 2016. [PubMed HealthCanada.1]
  76. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47(3):264-268. doi:10.1176/appi.psy.47.3.264 [PubMed 16684946]
  77. Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. J Am Geriatr Soc. 2017;65(12):2580-2586. doi:10.1111/jgs.15066 [PubMed 29095482]
  78. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492 [PubMed 28910830]
  79. Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol. 2006;26(2):167-171. doi:10.1097/01.jcp.0000203194.58087.9a [PubMed 16633146]
  80. Honigberg MC, Bui MP, Coconcea C. A case of ziprasidone associated with acutely worsened diabetes mellitus. Psychosomatics. 2013;54(3):304-305. doi:10.1016/j.psym.2012.08.011 [PubMed 23680062]
  81. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172 [PubMed 10671383]
  82. Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. J Clin Psychiatry. 2018;79(4):17m11764. doi: 10.4088/JCP.17m11764 [PubMed 29924506]
  83. Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. PLoS One. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376 [PubMed 25140533]
  84. Jones ME, Campbell G, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the General Practice Research Database. Cardiovasc Psychiatry Neurol. 2013;2013:647476. doi:10.1155/2013/647476 [PubMed 24416588]
  85. Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. J Am Geriatr Soc. 1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x [PubMed 3819263]
  86. Karamustafalioglu N, Kalelioglu T, Tanriover O, Gungor FC, Genc A, Ilnem C. A case report of priapism caused by ziprasidon. Psychiatry Investig. 2013;10(4):425-427. doi:10.4306/pi.2013.10.4.425 [PubMed 24474994]
  87. Keck ME, Müller MB, Binder EB, Sonntag A, Holsboer F. Ziprasidone-related tardive dyskinesia. Am J Psychiatry. 2004;161(1):175-176. doi:10.1176/appi.ajp.161.1.175-a [PubMed 14702272]
  88. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901 [PubMed 32867516]
  89. Khan SS and Mican LM, "A Naturalistic Evaluation of Intramuscular Ziprasidone Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Children and Adolescents," J Child Adolesc Psychopharmacol, 2006, 16(6):671-7. [PubMed 17201611]
  90. Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiol Res Pract. 2014;2014:273060. doi:10.1155/2014/273060 [PubMed 24649390]
  91. Kim MS, Kim SW, Han TY, Son SJ, Lee JH, Kim EJ. Ziprasidone-induced hypersensitivity syndrome confirmed by reintroduction. Int J Dermatol. 2014;53(4):e267-e268. doi:10.1111/ijd.12246 [PubMed 24117439]
  92. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. Hum Psychopharmacol. 2003;18(4):301-309. doi:10.1002/hup.483 [PubMed 12766935]
  93. Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol. 2005;6(3):148-157. [PubMed 15869022]
  94. Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. Ann Pharmacother. 2005;39(11):1940-1942. doi:10.1345/aph.1G130 [PubMed 16174785]
  95. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007;68(suppl 6):10-13. [PubMed 17650054]
  96. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007 [PubMed 24016844]
  97. Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1‐28. doi:10.1111/acps.12479 [PubMed 26344706]
  98. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56. [PubMed 15000267]
  99. Létourneau G, Abdel-Baki A, Dubreucq S, Mahone M, Granger B. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report. J Clin Psychopharmacol. 2011;31(5):671-673. doi:10.1097/JCP.0b013e31822c96b7 [PubMed 21881458]
  100. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010;36(3):624-632. doi:10.1093/schbul/sbn120 [PubMed 18849294]
  101. Lincoln J, Steward ME, Preskorn SH. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. J Psychiatr Pract. 2010;16(2):103-114. doi:10.1097/01.pra.0000369971.64908.dc [PubMed 20511734]
  102. Lin PY, Hong CJ, Tsai SJ. Serotonin syndrome caused by ziprasidone alone. Psychiatry Clin Neurosci. 2010;64(3):338-339. doi:10.1111/j.1440-1819.2010.02086.x [PubMed 20602736]
  103. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017;8:CD008559. [PubMed 28791693]
  104. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291-3301. [PubMed 20213839]
  105. Lusskin SI, Cancro R, Chuang L, Jacobson J. Prolactin elevation with ziprasidone. Am J Psychiatry. 2004;161(10):1925. doi:10.1176/ajp.161.10.1925 [PubMed 15465997]
  106. Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. Pharmacopsychiatry. 2004;37(3):134-138. [PubMed 15138897]
  107. Malone RP, Delaney MA, Hyman SB, et al, "Ziprasidone in Adolescents With Autism: An Open-Label Pilot Study," J Child Adolesc Psychopharmacol, 2007, 17(6):779-90. [PubMed 18315450]
  108. Marshall J, Herzig SJ, Howell MD, et al. Antipsychotic utilization in the intensive care unit and in transitions of care. J Crit Care. 2016;33:119-124. doi:10.1016/j.jcrc.2015.12.017 [PubMed 26818629]
  109. Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 2005;12(12):1167-1172. doi:10.1197/j.aem.2005.07.017 [PubMed 16282517]
  110. Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. South Med J. 2002;95(8):799-802. [PubMed 12190212]
  111. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018 [PubMed 25786075]
  112. McDougle CJ, Kem DL, and Posey DJ, "Case Series: Use of Ziprasidone for Maladaptive Symptoms in Youths With Autism," J Am Acad Child Adolesc Psychiatry, 2002, 41(8):921-7. [PubMed 12164181]
  113. Mechcatie, E, "MD Consult: News: Mixed Votes on Ziprasidone's Safety and Efficacy for Pediatric Indications," June 16, 2009. Date accessed: January 20, 2010. [PubMed Mechcatie.1]
  114. Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. Ther Adv Psychopharmacol. Published online July 6, 2020. doi:10.1177/2045125320937910 [PubMed 32670542]
  115. Montgomery J. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. Gen Hosp Psychiatry. 2006;28(1):83-85. doi:10.1016/j.genhosppsych.2005.08.005 [PubMed 16377373]
  116. Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 27, 2020. [PubMed Moore.2020]
  117. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007 [PubMed 8102845]
  118. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622 [PubMed 20187598]
  119. Murty RG, Mistry SG, Chacko RC. Neuroleptic malignant syndrome with ziprasidone. J Clin Psychopharmacol. 2002;22(6):624-626. doi:10.1097/00004714-200212000-00015 [PubMed 12454565]
  120. Nair P, Lippmann S. Blood dyscrasia with quetiapine and ziprasidone. Psychosomatics. 2005;46(1):89-90. doi:10.1176/appi.psy.46.1.89 [PubMed 15765830]
  121. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004;26(12):1936-1946. doi:10.1016/j.clinthera.2004.12.003 [PubMed 15823759]
  122. Nguyen T, Stanton J, Foster R. Intramuscular ziprasidone dosing for acute agitation in the pediatric emergency department: an observational study. J Pharm Pract. 2018;31(1):18-21. [PubMed 28205446]
  123. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997-2004. doi:10.1038/npp.2010.78 [PubMed 20520598]
  124. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57(8):512-518. doi: 10.1177/070674371205700810 [PubMed 22854034]
  125. O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. Ann Pharmacother. 2003;37(11):1675-1684. doi:10.1345/aph.1D056 [PubMed 14565800]
  126. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry. 2007;8(1):42-44. doi:10.1080/15622970600774202 [PubMed 17366349]
  127. Pagsberg AK, Tarp S, Glintborg D, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(3):191-202. [PubMed 28219485]
  128. Papakostas GI, Fava M, Baer L, et al. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2015;172(12):1251-1258. doi:10.1176/appi.ajp.2015.14101251 [PubMed 26085041]
  129. Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol. 2019;19(1):174. doi:10.1186/s12883-019-1385-4 [PubMed 31325958]
  130. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163 [PubMed 9735957]
  131. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-453. doi:10.1007/s40263-014-0157-3 [PubMed 24677189]
  132. Politte LC, McDougle CJ. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2014;231(6):1023-1036. [PubMed 23552907]
  133. Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 30, 2021. [PubMed Post.1]
  134. Praharaj SK, Jana AK, Sarkhel S, Sinha VK. Acute dystonia, akathisia, and parkinsonism induced by ziprasidone. Am J Ther. 2014;21(2):e38-40. doi:10.1097/MJT.0b013e318230ae52. [PubMed 23698184]
  135. Raza S, Haq F. Ziprasidone-induced galactorrhea in an adolescent female: a case report. Prim Care Companion J Clin Psychiatry. 2010;12(3):PCC.09l00855. doi:10.4088/PCC.09l00855gry [PubMed 20944784]
  136. Refer to manufacturer's labeling. [PubMed Manu.1]
  137. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res. 2005;76(2-3):267-272. doi:10.1016/j.schres.2005.01.009 [PubMed 15949658]
  138. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi:10.1176/appi.ajp.2015.173501 [PubMed 27133416]
  139. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426 [PubMed 14999113]
  140. Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022 [PubMed 26218604]
  141. Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. 2010;2010:159402. doi:10.1155/2010/159402 [PubMed 20871665]
  142. Rothschild AJ. Unipolar major depression with psychotic features: acute treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 4, 2020
  143. Sachs GS, Vanderburg DG, Karayal ON, Kolluri S, Bachinsky M, Cavus I. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2012;73(11):1412-1419. doi:10.4088/JCP.11m07388 [PubMed 23218157]
  144. Sallee FR, Kurlan R, Goetz CG, et al, “Ziprasidone Treatment of Children and Adolescents With Tourette's Syndrome: A Pilot Study,” J Am Acad Child Adolesc Psychiatry, 2000, 39(3):292-9. [PubMed 10714048]
  145. Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, Wilner K, Patel NC. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(6):720-728. [PubMed 16721322]
  146. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442-455. doi:10.1001/archpsyc.64.4.442 [PubMed 17404121]
  147. Schlotterbeck P, Saur R, Hiemke C, et al. Low concentration of ziprasidone in human milk: a case report. Int J Neuropsychopharmacol. 2009;12(3):437‐438. doi:10.1017/S1461145709009936 [PubMed 19203410]
  148. Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31. doi:10.1186/s13601-015-0073-8 [PubMed 26339470]
  149. Scott LK, Green R, McCarthy PJ, et al, "Agitation and/or Aggression After Traumatic Brain Injury in the Pediatric Population Treated With Ziprasidone. Clinical Article," J Neurosurg Pediatr, 2009, 3(6):484-7. [PubMed 19485732]
  150. Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8 [PubMed 19213967]
  151. Sethi R, Kavuru B. Hypothermia secondary to ziprasidone use in a man with schizophrenia. Prim Care Companion CNS Disord. 2012;14(4):PCC.11l01338. doi:10.4088/PCC.11l01338. [PubMed 23251855]
  152. Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract. 2014;20(3):196-206. doi:10.1097/01.pra.0000450319.21859.6d [PubMed 24847993]
  153. Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. Sleep Med. 2011;12(6):591-597. [PubMed 21645873]
  154. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159-169. [PubMed 17390261]
  155. Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. [PubMed 28721057]
  156. Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012 [PubMed 29439776]
  157. Staller JA, "Intramuscular Ziprasidone in Youth: A Retrospective Chart Review," J Child Adolesc Psychopharmacol, 2004, 14(4):590-2. [PubMed 15662151]
  158. Stovall J. Bipolar mania and hypomania in adults: choosing pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 10, 2021. [PubMed Stovall.2020]
  159. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-356. doi:10.1002/wps.20567 [PubMed 30192094]
  160. Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 28, 2022. [PubMed Stroup.1]
  161. Suh KN. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 27, 2020. [PubMed Suh.2020]
  162. Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull. 2017;43(4):862-871. doi:10.1093/schbul/sbw171 [PubMed 28044008]
  163. Tietze K. Sedative-analgesic medications in critically ill adults: Properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 3, 2020. [PubMed Tietze.1]
  164. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905 [PubMed 32929996]
  165. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152 [PubMed 23716032]
  166. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651 [PubMed 24803473]
  167. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord. 2000;2(3 Pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x [PubMed 11249804]
  168. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. https://www.cdc.gov/niosh/docs/2016-161/default.html. Updated September 2016. Accessed January 5, 2024. [PubMed HHS.1]
  169. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623 [PubMed 10473482]
  170. van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. Eur J Clin Pharmacol. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4 [PubMed 17401555]
  171. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320 [PubMed 18348593]
  172. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71 [PubMed 23858394]
  173. Wang B, Franklin JM, Eddings W, Landon J, Kesselheim AS. Did FDA decision making affect anti-psychotic drug prescribing in children?: a time-trend analysis. PLoS One. 2016;11(3):e0152195. [PubMed 27032095]
  174. Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. J Clin Psychiatry. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051 [PubMed 27780320]
  175. Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. Braz J Med Biol Res. 2014;47(7):605-616. doi:10.1590/1414-431x20143672 [PubMed 24919175]
  176. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 2012;13(1):26-34. doi:10.5811/westjem.2011.9.6866 [PubMed 22461918]
  177. Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. Psychosomatics. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002 [PubMed 25497507]
  178. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170. doi:10.1111/bdi.12609 [PubMed 29536616]
  179. Zhang Y, Wang Q, Reynolds GP, et al. Metabolic effects of 7 antipsychotics on patients with schizophrenia: a short-rerm, randomized, open-label, multicenter, pharmacologic trial. J Clin Psychiatry. 2020;81(3):19m12785. doi:10.4088/JCP.19m12785 [PubMed 32237292]
  180. Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a systematic review. Front Psychiatry. 2017;8:165. doi:10.3389/fpsyt.2017.00165 [PubMed 28936184]
Topic 10040 Version 545.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟